BBBruna Brands

Bruna Brands

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bruna Brands has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Impact of Benzodiazepine Use on Methadone Maintenance Treatment Outcomes

    by Bruna Brands, Joan Blake, David C. Marsh, Beth Sproule, Renuka Jeyapalan, Selina Li

    The purposes of this study were to examine predictors of benzodiazepine use among methadone maintenance treatment patients, to determine whether baseline benzodiazepine use influenced ongoing use during methadone maintenance treatment, and to assess the effect of ongoing benzodiazepine use on treatment outcomes (i.e., opioid and cocaine use and treatment retention). A retrospective chart review of 172 methadone maintenance treatment patients (mean age = 34.6 years; standard deviation = 8.5 years; 64% male) from January 1997 to December 1999 was conducted. At baseline, 29% were “non-users” (past year) of benzodiazepine, 36% were “occasional users,” and 35% were “regular/problem users.” Regular/problem users were more likely to have started opioid use with prescription opioids, experienced more overdoses, and reported psychiatric comorbidity. Being female, more years of opioid use, and a history of psychiatric treatment were significant predictors of baseline benzodiazepine use. Ongoing benzodiazepine users were more likely to have opioid-positive and cocaine-positive urine screens during methadone maintenance treatment. Only ongoing cocaine use was negatively related to retention. Benzodiazepine use by methadone maintenance treatment patients is associated with a more complex clinical picture and may negatively influence treatment outcomes.


  • The Expansion of Methadone Prescribing in Ontario, 1996–1998

    by John Brands, Bruna Brands, David Marsh

    Various Ontario agencies have co-operated to increase the availability of methadone maintenance treatment (MMT) across Ontario. It is expected that increased availability of MMT will lead to a reduction in some of the harms of opioid use, such as HIV infection acquired through needle use. This initiative is consistent with Canada's Drug Strategy and with MMT policy changes at the federal level and is responsive to concerns of methadone patient advocates and treatment providers. When the Methadone Program at The College of Physicians and Surgeons of Ontario was established in mid-1996, there were 975 patients in MMT across Ontario. At the end of 1998 - two and a half years later - there were over 4000. This expansion is attributed to policy changes at the provincial level which were facilitated by the development of MMT guidelines compatible with both harm reduction-based and abstinence-based treatment approaches and the development of a MMT training program and supporting reference materials.